Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome

Completed · Phase 2 · Has a placebo group

Conditions studied: Tobacco Abstinence Syndrome

In brief

This study will evaluate safety and efficacy of intranasal insulin in abstinent smokers. Groups' (placebo vs. insulin) cognitive function and stress response will be compared.

Key facts

Study ID

NCT01781234

Run by

Ajna Hamidovic

People needed

51

Starts

2013-08-01

Expected to finish

2016-05-01

Last updated by the study team

2018-12-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• smokers (>10 cig/day) for the past 1 year
• normosmic olfactory function

You may not qualify if…

• previous/current use of insulin
• current Diagnostic and Statistical Manual-IV-Revised (DSM-IV-R) Axis I disorder
• current pregnancy (or lactation)
• lifetime history of endocrine disease
• excessive alcohol use (>25 standard units of alcohol/week)
• current use of illicit drugs
• current use of a smoking cessation aid (NRT, Chantix or Wellbutrin), or a psychotropic agent
• local infections, inflammation, structural abnormalities, or other nasal pathology
• current use of any medications administered intranasally, including intranasal steroids

Where it is running

• UNM College of Pharmacy — Albuquerque, New Mexico, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.